Clinical Trial

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Study acronym: ELLIPSE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-02; most recent amendment 2025-05-27.
Status change: Recruiting → Active, Not Recruiting 2025-05-27
Status change: Not Yet Recruiting → Recruiting 2023-11-22
Trial Details
NCT Number NCT05975554
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Conditions TIA, Carotid Artery Plaque, Carotid Atherosclerosis
Enrollment 30 participants
Start Date 2023-08-26
Primary Completion 2025-02-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-30